|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:awards
|
gptkb:Prix_Galien
|
|
gptkbp:CEO
|
gptkb:Thomas_Schinecker
|
|
gptkbp:country
|
gptkb:Switzerland
|
|
gptkbp:division
|
Pharmaceuticals
Diagnostics
|
|
gptkbp:focus
|
Neuroscience
Oncology
Immunology
Infectious diseases
Ophthalmology
|
|
gptkbp:founded
|
1896
|
|
gptkbp:founder
|
gptkb:Fritz_Hoffmann-La_Roche
|
|
gptkbp:headquartersLocation
|
gptkb:Basel,_Switzerland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Roche Pharmaceuticals
|
|
gptkbp:industry
|
gptkb:biotechnology
Pharmaceuticals
|
|
gptkbp:keyPerson
|
gptkb:Severin_Schwan
gptkb:Christoph_Franz
gptkb:Thomas_Schinecker
|
|
gptkbp:languageOfWork
|
gptkb:German
English
|
|
gptkbp:listedOn
|
gptkb:SIX_Swiss_Exchange
|
|
gptkbp:logo
|
Roche logo.svg
|
|
gptkbp:marketCap
|
over CHF 200 billion (2023)
|
|
gptkbp:memberOf
|
gptkb:International_Federation_of_Pharmaceutical_Manufacturers_&_Associations
gptkb:European_Federation_of_Pharmaceutical_Industries_and_Associations
|
|
gptkbp:netIncome
|
CHF 13.5 billion (2023)
|
|
gptkbp:notableAcquisition
|
gptkb:Foundation_Medicine_(2018)
gptkb:Genentech_(2009)
Flatiron Health (2018)
Spark Therapeutics (2019)
|
|
gptkbp:numberOfEmployees
|
over 100,000
|
|
gptkbp:parentCompany
|
gptkb:F._Hoffmann-La_Roche_AG
|
|
gptkbp:products
|
gptkb:Actemra
gptkb:Avastin
gptkb:Herceptin
gptkb:Ocrevus
gptkb:Perjeta
gptkb:Rituxan
gptkb:Tamiflu
gptkb:Tecentriq
gptkb:Xeloda
|
|
gptkbp:revenue
|
CHF 63.3 billion (2023)
|
|
gptkbp:servesArea
|
Worldwide
|
|
gptkbp:stockExchange
|
gptkb:SIX_Swiss_Exchange
|
|
gptkbp:stockSymbol
|
gptkb:ROG
|
|
gptkbp:subsidiary
|
gptkb:Genentech
gptkb:Chugai_Pharmaceutical
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
https://www.roche.com/
|
|
gptkbp:bfsParent
|
gptkb:Roche
|
|
gptkbp:bfsLayer
|
6
|